Quill SRS Monoderm, which is made from a rapidly resorbing polymer, is intended primarily for superficial wound closure applications and indicated for soft tissue approximation where use of an absorbable suture is appropriate.
The product will be available immediately for distribution and sale in the US and Europe.
William Hunter, president and CEO of Angiotech, said: “The launch of Monoderm is another example of the progress we have made in expanding the Quill SRS product line. Monoderm is intended primarily for skin closure and will complement Quill SRS which currently targets deeper layers of wound closure.”